AbbVie bases Alzheimer’s effort in Cambridge

Comments Print Craig F. Walker/Globe Staff AbbVie Inc. vice president Eric Karran and chief scientific officer Michael Severino at the company’s new research facility in Cambridge. CAMBRIDGE — AbbVie Inc. will direct an effort to cure Alzheimer’s disease from its new research facility in Cambridge. The drug maker, based in North Chicago, Ill., on Wednesday formally opened a 43,000-square-foot Foundational Neuroscience Center on two floors of a former Vertex Pharmaceuticals Inc. building on Sidney Street. AbbVie vice president Eric Karran, a biopharma veteran hired from the United Kingdom to lead the new center, said its mission is ambitious: to take on Alzheimer’s, the neurodegenerative disease estimated to affect more than 40 million people worldwide. “There’s a group of people who don’t know about the Foundational Neuroscience Center, but they will,”…


Link to Full Article: AbbVie bases Alzheimer’s effort in Cambridge